Pinpoint Genomics Inc has published key data relating to its Pinpoint Dx Lung™ Assay in the journal The Lancet.
The Pinpoint Dx Lung Assay is a molecular diagnostic assay that differentiates between patients at high, intermediate or low risk of early death after surgery to remove a non-squamous, non-small cell lung cancer, the most common form of lung cancer.
The report in The Lancet describes the development of the assay based on specimens from 361 patients who underwent surgery at the University of California, San Francisco (UCSF), as well as the results of the two largest independent, blinded studies to evaluate the clinical validity of a multi-gene molecular diagnostic assay for early stage lung cancer. The two validation studies, conducted by the Kaiser Permanente Division of Research and the China Clinical Trials Consortium, involved 433 patients from northern California and 1,006 patients from several leading cancer centers in China, respectively.
Source: Pinpoint Genomics Inc
